Meet a faster way to access genomic screening, enrol patients, and set up biomarker-led clinical trials with Omico.
Researchers
Omico are increasing clinical trial efficiency and reducing costs through our fast tracked molecular and genomic screening, with patient enrolment from the entire nation.
Omico also provides greater innovation through access to a national network of thought leaders to expand capabilities and knowledge base.
Creating possibilities for clinical trials
Why work with Omico?
1
Perform intellectually-stimulating world-class research.
2
Access patient-focused opportunities that change cancer care and transform lives.
3
Access state-of-the-art genomics and correlative science resources.
4
Join and collaborate with a national network of thought leaders.
Finding new treatment paths for difficult-to-treat cancers
Omico’s landmark Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) aims to open up new options for patients with difficult-to-treat, advanced and metastatic cancers.
Matching patients to biomarker-led clinical trials
Through our Cancer Screening Project (CaSP) we’re performing comprehensive genomic profiling for cancer patients with unmet clinical need to match them to clinical trials or other care pathways.
Matching molecular changes to targeted therapy
Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.
Identifying genetic basis of cancer risk
We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.
Improving surveillance of multi-organ cancer
Our Surveillance study in Multi-Organ Cancer-prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high risk of multi-organ cancer.
Who we work with
